Equities

Sanofi India Ltd

SANOFI:NSI

Sanofi India Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)6,054.05
  • Today's Change-24.95 / -0.41%
  • Shares traded14.32k
  • 1 Year change+22.88%
  • Beta0.6181
Data delayed at least 15 minutes, as of Nov 22 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Sanofi India Ltd have a median target of 7,560.00, with a high estimate of 9,345.00 and a low estimate of 7,421.00. The median estimate represents a 24.75% increase from the last price of 6,060.00.
High54.2%9,345.00
Med24.8%7,560.00
Low22.5%7,421.00

Dividends

In 2023, Sanofi India Ltd reported a dividend of 167.00 INR, which represents a 13.92% decrease from last year. The analyst covering the company expects dividends of 50.00 INR for the upcoming fiscal year, a decrease of 70.06%.
Div growth (TTM)-13.92%
More ▼

Earnings history & estimates in INR

On Feb 23, 2024, earnings of 59.79 per share.
The next earnings announcement is expected on Feb 21, 2025.
Average growth rate+43.16%
Sanofi India Ltd reported annual 2023 earnings of 254.05 per share on Feb 23, 2024.
Average growth rate+6.10%
More ▼

Revenue history & estimates in INR

of 6.94bn. This missed the 7.12bn consensus estimate of the 2 analysts following the company.
Average growth rate+0.95%
Sanofi India Limited had revenues for the full year 2023 of 28.51bn. This was 2.92% above the prior year's results.
Average growth rate-1.75%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.